Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials - PubMed
3 hours ago
- #obesity
- #type 2 diabetes
- #semaglutide
- Semaglutide is a leading therapy for metabolic disorders, including obesity and type 2 diabetes, with cardiovascular and renal benefits.
- A meta-analysis of 33 randomized controlled trials (RCTs) involving 21,023 participants found suboptimal therapeutic responses to semaglutide.
- 33.4% of participants did not achieve ≥5% total body weight reduction, and 65.1% did not achieve ≥10% weight reduction.
- Patients with type 2 diabetes mellitus (T2DM) had higher rates of suboptimal outcomes, with up to 79.8% not achieving ≥10% weight loss, compared to 30.1% in non-T2DM individuals.
- A significant proportion of patients discontinue semaglutide due to adverse events or insufficient weight/glycemic improvements.
- The study highlights the need for further research into optimizing semaglutide therapy for non-responders.